The FDA has approved desmopressin acetate oral solution (Desmoda) from Eton Pharmaceuticals for the treatment of central diabetes insipidus in adult and pediatric patients.[1][2][3] Desmoda is a vasopressin analog that acts as an antidiuretic and replaces the lack of this hormone from the hypothalamus or posterior pituitary gland.[1][2] It is the first and only approved 0.05 mg/mL oral liquid formulation of desmopressin that does not require tablet splitting, crushing, refrigeration, mixing, or shaking.[1][2][7] The formulation allows for precise individual dosing, which is key to maintaining water balance in the body and avoiding complications from overdosing or underdosing.[1][2][4] More than 13,000 patients in the US suffer from this rare disease, including 3,000 to 4,000 children.[1][2] Desmoda is expected to be on the market from March 9, 2026 exclusively through the specialized pharmacy Anovo.[1][2][7] The product has patent protection until 2044 and estimated maximum annual sales of 30 to 50 million dollars.[1][2] It is Eton Pharmaceuticals' ninth approved product.[2]